Cargando…
Reappraisal of the management of Vogt–Koyanagi–Harada disease: sunset glow fundus is no more a fatality
PURPOSE: Vogt–Koyanagi–Harada (VKH) disease is a primary autoimmune stromal choroiditis. Aim of the study was to gather a body of evidence from the literature and from experts that systemic corticosteroid combined with non-steroidal immunosuppressive therapy should become the standard of care in ini...
Autores principales: | Herbort Jr, Carl P., Abu El Asrar, Ahmed M., Yamamoto, Joyce H., Pavésio, Carlos E., Gupta, Vishali, Khairallah, Moncef, Tugal-Tutkun, Ilknur, Soheilian, Masoud, Takeuchi, Masuru, Papadia, Marina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660833/ https://www.ncbi.nlm.nih.gov/pubmed/27844182 http://dx.doi.org/10.1007/s10792-016-0395-0 |
Ejemplares similares
-
Identification of Underlying Inflammation in Vogt–Koyanagi–Harada Disease with Sunset Glow Fundus by Multiple Analyses
por: Murata, Toshihiko, et al.
Publicado: (2019) -
Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study
por: Takeuchi, Masaru, et al.
Publicado: (2022) -
Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs
por: Komuku, Yuki, et al.
Publicado: (2020) -
Early post-treatment choroidal thickness to alert sunset glow fundus in patients with Vogt-Koyanagi-Harada disease treated with systemic corticosteroids
por: Hirooka, Kiriko, et al.
Publicado: (2017) -
“Revised diagnostic criteria” for Vogt-Koyanagi-Harada disease fail to improve disease management
por: Hedayatfar, Alireza, et al.
Publicado: (2018)